The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Antibody-Drug Conjugates for Cancer Therapy
Abstract
The antibody-drug conjugate (ADC) concept is to use an antibody to deliver a cytotoxic drug selectively to a target such as a tumor-associated antigen. Such conjugates represent a broadly applicable approach to enhance the antitumor activity of antibodies and improve the tumor-to-normal tissue selectivity of chemotherapy. Critical parameters for ADC development include target antigen selection, conjugate internalization by tumor cells, drug potency and stability of the linker between drug and antibody. Other important considerations include the conjugation methods, drug-to-antibody ratio, and the effects of drug conjugation on antibody properties. Highly potent drugs with more stable linkers have been attached to a new generation of antibodies to create conjugates with pronounced antitumor activities in preclinical studies and encouraging results in early stage clinical trials. This review details these advances, discusses some of the remaining challenges, and overviews ADCs currently in clinical trials for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Smith, D. B., & Johnson, K. S. (1988) · Gene · doi:10.1016/0378-1119(88)90005-4 · Cited by 5,892
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Self-citationSmith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,507
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Self-citationDevelopment of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Self-citationShields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Self-citationArming antibodies: prospects and challenges for immunoconjugates
Wu, A. M., & Senter, P. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1141 · Cited by 1,052
Self-citationAnti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange
van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W. K., Martínez-Martínez, P., Vermeulen, E., den Bleker, T. H., Wiegman, L., Vink, T., Aarden, L. A., et al. (2007) · Science · doi:10.1126/science.1144603 · Cited by 975
Selecting and screening recombinant antibody libraries
Hoogenboom, H. R. (2005) · Nature Biotechnology · doi:10.1038/nbt1126 · Cited by 973
Discordant Protein and mRNA Expression in Lung Adenocarcinomas
Chen, G., Gharib, T. G., Huang, C.-C., Taylor, J. M. G., Misek, D. E., Kardia, S. L. R., Giordano, T. J., Iannettoni, M. D., Orringer, M. B., Hanash, S. M., et al. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m200008-mcp200 · Cited by 946
Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
Self-citationSievers, E. L., Larson, R. A., Stadtmauer, E. A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J. M., Sherman, M. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3244 · Cited by 899
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 815
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex
Sondermann, P., Huber, R., Oosthuizen, V., & Jacob, U. (2000) · Nature · doi:10.1038/35018508 · Cited by 719
Flow cytometric immunophenotyping for hematologic neoplasms
Craig, F. E., & Foon, K. A. (2008) · Blood · doi:10.1182/blood-2007-11-120535 · Cited by 672
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall'Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 646
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., & Blättler, W. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4489 · Cited by 584
Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates
Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellström, I., & Hellström, K. E. (1993) · Science · doi:10.1126/science.8327892 · Cited by 556
Metabolic properties of IgG subclasses in man
Morell, A., Terry, W. D., & Waldmann, T. A. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106279 · Cited by 526
Lee, M. D., Dunne, T. S., Chang, C. C., Ellestad, G. A., Siegel, M. M., Morton, G. O., McGahren, W. J., & Borders, D. B. (1987) · Journal of the American Chemical Society · doi:10.1021/ja00245a051 · Cited by 523
Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0502917 · Cited by 515
Self-citationContribution of Linker Stability to the Activities of Anticancer Immunoconjugates
Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., & Senter, P. D. (2008) · Bioconjugate Chemistry · doi:10.1021/bc7004329 · Cited by 479
Self-citationKovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479
Larson, R. A., Sievers, E. L., Stadtmauer, E. A., Löwenberg, B., Estey, E. H., Dombret, H., Theobald, M., Voliotis, D., Bennett, J. M., Richie, M., et al. (2005) · Cancer · doi:10.1002/cncr.21326 · Cited by 460
Aalberse, R. C., & Schuurman, J. (2002) · Immunology · doi:10.1046/j.0019-2805.2001.01341.x · Cited by 449
Lee, M. D., Dunne, T. S., Siegel, M. M., Chang, C. C., Morton, G. O., & Borders, D. B. (1987) · Journal of the American Chemical Society · doi:10.1021/ja00245a050 · Cited by 392
Crystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc Complex
Martin, W. L., West, A. P., Gan, L., & Bjorkman, P. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00230-1 · Cited by 391
Development trends for monoclonal antibody cancer therapeutics
Reichert, J. M., & Valge-Archer, V. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2241 · Cited by 389
Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides
Sun, M. M. C., Beam, K. S., Cerveny, C. G., Hamblett, K. J., Blackmore, R. S., Torgov, M. Y., Handley, F. G. M., Ihle, N. C., Senter, P. D., & Alley, S. C. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050201y · Cited by 370
Self-citationDiJoseph, J. F., Armellino, D. C., Boghaert, E. R., Khandke, K., Dougher, M. M., Sridharan, L., Kunz, A., Hamann, P. R., Gorovits, B., Udata, C., et al. (2004) · Blood · doi:10.1182/blood-2003-07-2466 · Cited by 361
Dolastatin 10, a powerful cytostatic peptide derived from a marine animal
Bai, R., Petit, G. R., & Hamel, E. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90613-p · Cited by 321
Tijink, B. M., Buter, J., de Bree, R., Giaccone, G., Lang, M. S., Staab, A., Leemans, C. R., & van Dongen, G. A. M. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0910 · Cited by 315
Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn
Ober, R. J., Martinez, C., Vaccaro, C., Zhou, J., & Ward, E. S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2021 · Cited by 314
Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer
Widdison, W. C., Wilhelm, S. D., Cavanagh, E. E., Whiteman, K. R., Leece, B. A., Kovtun, Y., Goldmacher, V. S., Xie, H., Steeves, R. M., Lutz, R. J., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060319f · Cited by 309
Sutherland, M. S. K., Sanderson, R. J., Gordon, K. A., Andreyka, J., Cerveny, C. G., Yu, C., Lewis, T. S., Meyer, D. L., Zabinski, R. F., Doronina, S. O., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510026200 · Cited by 296
Self-citationAntibody therapeutics: isotype and glycoform selection
Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294
Yu, T.-W., Bai, L., Clade, D., Hoffmann, D., Toelzer, S., Trinh, K. Q., Xu, J., Moss, S. J., Leistner, E., & Floss, H. G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092697199 · Cited by 286
In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate
Sanderson, R. J., Hering, M. A., James, S. F., Sun, M. M. C., Doronina, S. O., Siadak, A. W., Senter, P. D., & Wahl, A. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.843.11.2 · Cited by 285
Self-citationGiles, F. J., Kantarjian, H. M., Kornblau, S. M., Thomas, D. A., Garcia-Manero, G., Waddelow, T. A., David, C. L., Phan, A. T., Colburn, D. E., Rashid, A., et al. (2001) · Cancer · doi:10.1002/1097-0142(20010715)92:2<406::aid-cncr1336>3.0.co;2-u · Cited by 283
An Engineered Human IgG1 Antibody with Longer Serum Half-Life
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282
Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
Dubowchik, G. M., & Walker, M. A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00018-2 · Cited by 277
Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates
Hinton, P. R., Johlfs, M. G., Xiong, J. M., Hanestad, K., Ong, K. C., Bullock, C., Keller, S., Tang, M. T., Tso, J. Y., Vásquez, M., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300470200 · Cited by 273
Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer
Tolcher, A. W., Sugarman, S., Gelmon, K. A., Cohen, R., Saleh, M., Isaacs, C., Young, L., Healey, D., Onetto, N., & Slichenmyer, W. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.478 · Cited by 271
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
CHARI, R. V. J., Martell, B., Gross, J. L., Cook, S., Shah, S. A., Blättler, W. A., McKenzie, S. J., & Goldmacher, V. S. (1992) · PubMed · Cited by 266
Exocytosis of IgG as mediated by the receptor, FcRn: An analysis at the single-molecule level
Ober, R. J., Martinez, C., Lai, X., Zhou, J., & Ward, E. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402970101 · Cited by 258
West, A. P., & Bjorkman, P. J. (2000) · Biochemistry · doi:10.1021/bi000749m · Cited by 257
Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy
Rajvanshi, P., Shulman, H. M., Sievers, E. L., & McDonald, G. B. (2002) · Blood · doi:10.1182/blood.v99.7.2310 · Cited by 246
Cell killing by antibody–drug conjugates
Kovtun, Y. V., & Goldmacher, V. S. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.04.010 · Cited by 246
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
McDonagh, C. F., Turcott, E., Westendorf, L., Webster, J. B., Alley, S. C., Kim, K., Andreyka, J., Stone, I., Hamblett, K. J., Francisco, J. A., et al. (2006) · Protein Engineering Design and Selection · doi:10.1093/protein/gzl013 · Cited by 243
Self-citationIsotype selection in antibody engineering
Salfeld, J. G. (2007) · Nature Biotechnology · doi:10.1038/nbt1207-1369 · Cited by 239
Hinman, L. M., Hamann, P. R., Wallace, R., Menendez, A. T., Durr, F. E., & Upeslacis, J. (1993) · PubMed · Cited by 236
Jakobovits, A., Amado, R. G., Yang, X., Roskos, L., & Schwab, G. (2007) · Nature Biotechnology · doi:10.1038/nbt1337 · Cited by 230
Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Flowers, D. A., & Bernstein, I. (2002) · Bioconjugate Chemistry · doi:10.1021/bc0100206 · Cited by 230
Almagro, J. C., & Fransson, J. (2008) · PubMed · doi:10.2741/2786 · Cited by 220
Drug-conjugated monoclonal antibodies for the treatment of cancer
LAMBERT, J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.017 · Cited by 210
Tolcher, A. W., Ochoa, L., Hammond, L. A., Patnaik, A., Edwards, T., Takimoto, C., Smith, L., de Bono, J., Schwartz, G., Mays, T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.137 · Cited by 206
Saleh, M. N., Sugarman, S., Murray, J., Ostroff, J. B., Healey, D., Jones, D., Daniel, C. R., LeBherz, D., Brewer, H., Onetto, N., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2282 · Cited by 196
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.
Liu, C., Tadayoni, B. M., Bourret, L. A., Mattocks, K. M., Derr, S. M., Widdison, W. C., Kedersha, N. L., Ariniello, P. D., Goldmacher, V. S., Lambert, J. M., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8618 · Cited by 196
Tissue microarrays in drug discovery
Sauter, G., Simon, R., & Hillan, K. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1254 · Cited by 194
Dubowchik, G. M., & Firestone, R. A. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00609-x · Cited by 188
CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
Tse, K. F., Jeffers, M., Pollack, V. A., McCabe, D. A., Shadish, M. L., Khramtsov, N. V., Hackett, C. S., Shenoy, S. G., Kuang, B., Boldog, F. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2018 · Cited by 183
Self-citationAntibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma
Polson, A. G., Yu, S.-F., Elkins, K., Zheng, B., Clark, S., Ingle, G. S., Slaga, D. S., Giere, L., Du, C., Tan, C., et al. (2007) · Blood · doi:10.1182/blood-2007-01-066704 · Cited by 173
Moolten, F. L., & Cooperband, S. R. (1970) · Science · doi:10.1126/science.169.3940.68 · Cited by 167
Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs
Junutula, J. R., Bhakta, S., Raab, H., Ervin, K. E., Eigenbrot, C., Vandlen, R., Scheller, R. H., & Lowman, H. B. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.12.011 · Cited by 165
Transcytosis and Catabolism of Antibody
Ghetie, V. F., & Ward, E. S. (2002) · Immunologic Research · doi:10.1385/ir:25:2:097 · Cited by 163
Law, C., Gordon, K. A., Toki, B. E., Yamane, A. K., Hering, M. A., Cerveny, C. G., Petroziello, J. M., Ryan, M. C., Smith, L. M., Simon, R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2883 · Cited by 160
Self-citationHenry, M. D., Wen, S., Silva, M. D., Chandra, S., Milton, M., & Worland, P. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1722 · Cited by 156
Antibody-targeted chemotherapy with immunoconjugates of calicheamicin
Damle, N. K. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00083-3 · Cited by 155
Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective
Desjarlais, J. R., Lazar, G. A., Zhukovsky, E. A., & Chu, S. Y. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.009 · Cited by 154
Tassone, P., Gozzini, A., Goldmacher, V. S., Shammas, M. A., Whiteman, K. R., Carrasco, D. R., Li, C., Allam, C. K., Venuta, S., Anderson, K. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0142 · Cited by 152
Baeckström, D., Hansson, G. C., Nilsson, O., Johansson, C., Gendler, S. J., & Lindholm, L. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54672-x · Cited by 148
Drewinko, B., Patchen, M. L., Yang, L., et al. (1981) · PubMed · Cited by 148
Toward Selection of Internalizing Antibodies from Phage Libraries
Becerril, B., Poul, M., & Marks, J. D. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0177 · Cited by 147
Ross, S., Spencer, S. D., Holcomb, I. N., Tan, C., Hongo, J.-A., Devaux, B., Rangell, L. K., Keller, G. A., Schow, P. W., Steeves, R. M., et al. (2002) · PubMed · Cited by 144
Xie, H., Audette, C. A., Hoffee, M., Lambert, J. M., & Blättler, W. A. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060533 · Cited by 142
DiJoseph, J. F., Dougher, M. M., Kalyandrug, L. B., Armellino, D. C., Boghaert, E. R., Hamann, P. R., Moran, J. K., & Damle, N. K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1905 · Cited by 140
Ma, D., Hopf, C. E., Malewicz, A. D., Donovan, G. P., Senter, P. D., Goeckeler, W. F., Maddon, P. J., & Olson, W. C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2107 · Cited by 139
Self-citationModulation of the Effector Functions of a Human IgG1 through Engineering of Its Hinge Region
Dall’Acqua, W. F., Cook, K. E., Damschroder, M. M., Woods, R. M., & Wu, H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1129 · Cited by 138
King, D., Dubowchik, G. M., Mastalerz, H. A., Willner, D., Hofstead, S. J., Firestone, R. A., Lasch, S. J., & Trail, P. A. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020149g · Cited by 135
DiJoseph, J. F., Dougher, M. M., Armellino, D. C., Evans, D. Y., & Damle, N. K. (2007) · Leukemia · doi:10.1038/sj.leu.2404866 · Cited by 134
Identification and validation of cell surface antigens for antibody targeting in oncology
Carter, P. M., Smith, L. M., & Ryan, M. C. (2004) · Endocrine Related Cancer · doi:10.1677/erc.1.00766 · Cited by 129
Self-citationEphB2 as a Therapeutic Antibody Drug Target for the Treatment of Colorectal Cancer
Mao, W., Luis, E., Ross, S., Silva, J., Tan, C., Crowley, C. W., Chui, C. H., Franz, G., Senter, P. D., Koeppen, H., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1047 · Cited by 127
Self-citationHuman IgG2 Can Form Covalent Dimers
Yoo, E. M., Wims, L. A., Chan, L. A., & Morrison, S. L. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3134 · Cited by 126
Tassone, P., Goldmacher, V. S., Neri, P., Gozzini, A., Shammas, M. A., Whiteman, K. R., Hylander-Gans, L., Carrasco, D. R., Hideshima, T., Shringarpure, R., et al. (2004) · Blood · doi:10.1182/blood-2004-03-0963 · Cited by 124
Differential distribution of free and bound glutathione and cyst(e)ine in human blood
Mills, B. J., & Lang, C. A. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00241-9 · Cited by 120
CHARI, R. V. J., Jackel, K. A., Bourret, L. A., Derr, S. M., Tadayoni, B. M., Mattocks, K. M., Shah, S., Liu, C., Blättler, W. A., & Goldmacher, V. S. (1995) · PubMed · Cited by 119
Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates
Law, C., Cerveny, C. G., Gordon, K. A., Klussman, K., Mixan, B. J., Chace, D. F., Meyer, D. L., Doronina, S. O., Siegall, C. B., Francisco, J. A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1028 · Cited by 116
Self-citationSmith, L. M., Nesterova, A., Alley, S. C., Torgov, M. Y., & Carter, P. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0026 · Cited by 108
Self-citationHuman Monoclonal Antibodies from Transgenic Mice
Lönberg, N. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_4 · Cited by 105
Antibody-based targeting of the tumor vasculature
Schliemann, C., & Neri, D. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.08.002 · Cited by 99
DiJoseph, J. F., Goad, M. E. P., Dougher, M. M., Boghaert, E. R., Kunz, A., Hamann, P. R., & Damle, N. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1134 · Cited by 99
Engineering Antibodies for Therapy
Presta, L. G. (2002) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023378256 · Cited by 94
Chen, Y., Clark, S., Wong, T., Chen, Y., Chen, Y., Dennis, M. S., Luis, E., Zhong, F., Bheddah, S., Koeppen, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4512 · Cited by 94
Targeting the neural cell adhesion molecule in cancer
Jensen, M., & Berthold, F. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.09.004 · Cited by 91
Antibody targeting of B-cell maturation antigen on malignant plasma cells
Ryan, M. C., Hering, M. A., Peckham, D., McDonagh, C. F., Brown, L. L., Kim, K. M., Meyer, D. L., Zabinski, R. F., Grewal, I. S., & Carter, P. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0464 · Cited by 89
Self-citationIngle, G. S., Chan, P., Elliott, J. M., Chang, W. S., Koeppen, H., Stéphan, J.-P., & Scales, S. J. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06883.x · Cited by 83
Pollack, V. A., Álvarez, E., Tse, K. F., Torgov, M. Y., Xie, S., Shenoy, S. G., MacDougall, J. R., Arrol, S., Zhong, H., Gerwien, R. W., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0490-z · Cited by 82
Self-citationBuilding better magic bullets — improving unconjugated monoclonal antibody therapy for cancer
Weiner, L. M. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2209 · Cited by 82
Hamann, P. R., Hinman, L. M., Beyer, C. F., Greenberger, L. M., Lin, C. J., Lindh, D., Menendez, A. T., Wallace, R., Durr, F. E., & Upeslacis, J. (2005) · Bioconjugate Chemistry · doi:10.1021/bc049795f · Cited by 81
Afar, D., Bhaskar, V., Ibsen, E. M., Breinberg, D., Henshall, S. M., Kench, J. G., Drobnjak, M., Powers, R., Wong, M. H. L., Evangelista, F., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.921.3.8 · Cited by 81
Hollander, I. J., Kunz, A., & Hamann, P. R. (2007) · Bioconjugate Chemistry · doi:10.1021/bc700321z · Cited by 80
Site-specific Conjugation on Serine → Cysteine Variant Monoclonal Antibodies
Stimmel, J. B., Merrill, B. M., Kuyper, L. F., Moxham, C. P., Hutchins, J. T., Fling, M. E., & Kull, F. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001672200 · Cited by 78
Boghaert, E. R., Khandke, K. M., Sridharan, L., Dougher, M. M., DiJoseph, J. F., Kunz, A., Hamann, P. R., Moran, J. K., Chaudhary, I., & Damle, N. K. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0560-2 · Cited by 66
Boghaert, E. R., Sridharan, L., Armellino, D. C., Khandke, K. M., DiJoseph, J. F., Kunz, A., Dougher, M. M., Jiang, F., Kalyandrug, L. B., Hamann, P. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0037 · Cited by 66
E-selectin up-regulation allows for targeted drug delivery in prostate cancer.
Bhaskar, V., Law, D. A., Ibsen, E. M., Breinberg, D., Cass, K. M., DuBridge, R. B., Evangelista, F., Henshall, S. M., Hevezi, P. A., Miller, J. C., et al. (2003) · PubMed · Cited by 65
Self-citationDiJoseph, J. F., Dougher, M. M., Armellino, D. C., Kalyandrug, L. B., Kunz, A., Boghaert, E. R., Hamann, P. R., & Damle, N. K. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0260-5 · Cited by 64
Human antibody libraries: A race to engineer and explore a larger diversity
Mondon, P., Dubreuil, O., Bouayadi, K., & Kharrat, H. (2007) · Frontiers in bioscience · doi:10.2741/2749 · Cited by 63
Perspectives on Anti-HER Monoclonal Antibodies
Ranson, M., & Sliwkowski, M. X. (2002) · Oncology · doi:10.1159/000066203 · Cited by 63
Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Shochat, D., & Mountain, A. (2005) · Bioconjugate Chemistry · doi:10.1021/bc049794n · Cited by 60
Minor groove binder antibody conjugates employing a water soluble β-glucuronide linker
Jeffrey, S. C., Nguyen, M. T., Moser, R. F., Meyer, D. L., Miyamoto, J. B., & Senter, P. D. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.071 · Cited by 59
Self-citationSynthesis of an immunoconjugate of camptothecin
Walker, M. A., Dubowchik, G. M., Hofstead, S. J., Trail, P. A., & Firestone, R. A. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00707-7 · Cited by 53
Haglund, C. H., Lindgren, J., Roberts, P., Kuusela, P., & Nordling, S. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.377 · Cited by 52
The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin g
Zuckier, L. S., Georgescu, L., Chang, C., Scharff, M. D., & Morrison, S. L. (1994) · Cancer · Cited by 52
Helft, P. R., Schilsky, R. L., Hoke, F., Williams, D., Kindler, H. L., Sprague, E., DeWitte, M., Martino, H. K., Erickson, J., Pandite, L. N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0088 · Cited by 52
Boghaert, E. R., Sridharan, L., Khandke, K. M., Armellino, D. C., Ryan, M., Myers, K. A., Harrop, R., Kunz, A., Hamann, P., Marquette, K., et al. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.1.221 · Cited by 41
Engineered humanized dimeric forms of IgG are more effective antibodies.
Caron, P. C., Laird, W., Co, M. S., Avdalovic, N. M., Queen, C., & Scheinberg, D. A. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.4.1191 · Cited by 40
Chemoimmunoconjugates for the Treatment of Cancer
Pietersz, G. A., Rowland, A. J., Smyth, M. J., & McKenzie, I. F. C. (1994) · Advances in immunology · doi:10.1016/s0065-2776(08)60455-1 · Cited by 38
αv Integrin-Targeted Immunoconjugates Regress Established Human Tumors in Xenograft Models
Chen, Q., Millar, H. J., McCabe, F. L., Manning, C. D., Steeves, R. M., Lai, K., Kellogg, B. A., Lutz, R. J., Trikha, M., Nakada, M. T., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0026 · Cited by 35
Vascular proteomic mapping in vivo
Simonson, A. B., & Schnitzer, J. E. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02551.x · Cited by 27
Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy
Brumlik, M. J., Daniel, B. J., Waehler, R., Curiel, D. T., Giles, F. J., & Curiel, T. J. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.1.87 · Cited by 27
In vivobehaviour of antibody–drug conjugates for the targeted treatment of cancer
Xie, H., & Blättler, W. A. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.3.281 · Cited by 24
Mita, M. M., Ricart, A. D., Mita, A. C., Patnaik, A., Sarantopoulos, J., Sankhala, K. K., Fram, R. J., Qin, A., Watermill, J., & Tolcher, A. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3062 · Cited by 24
Hamblett, K. J., Barton, J. E., Cerveny, C. G., et al. (2005) · Blood · doi:10.1182/blood.v106.11.610.610 · Cited by 17
Cited by
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Shen, B.-Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S.-F., Mai, E., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2108 · Cited by 1,008
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
Self-citationAntibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Self-citationSenter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763
Self-citation
Metadata
- Authors
- Carter, P. J., & Senter, P. D.
- Venue
- The Cancer Journal
- Published
- 2008-05
- Volume
- 14
- Issue
- 3
- Pages
- 154-169
- ISSN
- 1528-9117 (ISSN-L)
- OpenAlex
- W2083670340
- Cited by
- 429
- References
- 132
- FWCI
- 25.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.